SCHEMBL14246783

SCHEMBL14246783

COc1cc(OC)c2c(C)c(Cc3cccc(Cl)c3)c(=O)oc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.58
ALDH1A1 P00352 5/20 0.58
HPGD P15428 4/20 0.58
MAPT P10636 3/20 0.58
LMNA P02545 3/20 0.58
GAA P10253 2/20 0.58
HSD17B10 Q99714 2/20 0.58
MEN1 O00255 1/20 0.58
GLA P06280 1/20 0.58
KMT2A Q03164 1/20 0.58
TP53 P04637 2/20 0.52
MAOA P21397 3/20 0.47
ACHE P22303 1/20 0.47
MAOB P27338 1/20 0.47
CNR2 P34972 2/20 0.46
CNR1 P21554 2/20 0.46
CCR4 P51679 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
VKORC1 Q9BQB6 1/20 0.45
GPR55 Q9Y2T6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14305743 0.92 ALDH1A1 (0.48) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL15931664 0.85 ALDH1A1 (0.62) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL14246874 0.81 ALDH1A1 (0.56) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL14246722 0.78 PDE10A (0.43) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL8745812 0.78 ALDH1A1 (0.67) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL14317879 0.76 KDM4E (0.76) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL5328637 0.76 KDM4E (0.62) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL5327925 0.76 KDM4E (0.56) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL9588218 0.76 CNR2 (0.44) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL8745805 0.74 ALDH1A1 (0.61) KDM4EALDH1A1HPGDMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 US disclosed
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
EP-2720695-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NoNO Inc. (CA) 2014-04-23 EP disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 WO disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases TRPM7, TRPM8, TRPM5 KDM4E 4656/4885ALDH1A1 1722/4885HPGD 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.